الفهرس | Only 14 pages are availabe for public view |
Abstract Egypt, a lower middle-income country with a population of 100 million, had one of the highest burdens of HCV infections globally (Blach et al., 2017). By 2018, the program had evolved into a national strategy to eliminate HCV as a public health threat. This new strategy aligned with the first Global Health Sector Strategy on Viral Hepatitis 2016–2021 agenda that was unanimously adopted by the 194 World Health Organization (WHO) member states, including Egypt.4 WHO signatories committed to eliminating viral hepatitis as a public health threat by 2030. Elimination was defined by WHO as a 65% reduction in mortality and a 90% reduction in incidence, compared with the 2015 baseline (Organization 2016). During the past few years, there have been enormous efforts to understand the structure and life cycle of hepatitis C virus (HCV) and to develop specific medications targeting different viral proteins such as NS3/4A protease, NS5B polymerase, and NS5A replication complex. The discovery of direct acting antiviral agents (DAAs) represented a revolution in the management of chronic hepatitis C virus infection. The aim of the present study was to assess Prevalence and predictors of HCV relapse after direct acting antiviral drugs. The present study was retrospective study, data were analyzed from 422 consecutive patients with HCV, who were selected from those attending viral hepatitis C unit at Shebin El-khom teaching Hospital, Egypt from (March 2019 to March 2020). Patients were categorized to two group after assessment of Eligibility of each patient for treatment of hepatitis C with DAAs according to the guidelines of the NCCVH group (1): Easy-to-treat patients : - Patients who were treatment naïve and had no cirrhosis or had normal liver tests . - They were treated with SOF-DCV for 12 weeks without RBV. group (2): Difficult-to-treat patients: - Patients who had previously failed interferon or SOF-based therapy, patients with cirrhosis, and those who had serum albumin <3.5 g/dL, bilirubin >1.2 mg/dL, INR>1.2 and/or platelet count <150 000/cmm. They were treated with SOF-DCV-RBV for 12 weeks. All patients in the present study were subjected to history taking, full clinical examination, laboratory data (liver function profiles, prothrombin time (PT), renal function tests, complete blood count, serum alpha fetoprotein (AFP) and viral markers), Imaging data (Abdominal ultrasonography and Triphasic CT). |